Skip to main content
. 2020 Jul 7;21(13):4808. doi: 10.3390/ijms21134808

Figure 1.

Figure 1

Differentiation protocol and robustness: (A) A differentiation scheme indicating the different steps, including cytokines, growth factors, and medium conditions to obtain macrophage progenitors and macrophages from induced pluripotent stem cells (iPSCs). (B) Representative phase images of embryoid body (EB) adherence to uncoated and growth factor-reduced (GFR) Matrigel-coated dishes. (C) Myeloid marker genes and proliferation marker of macrophage progenitors sampled over the complete production period of a myeloid factory (n = 3; iPSC lines SFC840-03-01 (STBCi026-B), SFC831-03-03 (STBCi024-B), and SBNEO1). (D) Marker gene expression (CD68, IBA1, CD14, and CD11b) in macrophages differentiated from progenitors harvested at different time points of blood factory lifecycle (n = 3; iPSC line SFC840-03-01). (E) Comparison of differentiation times until start of macrophage precursor production and yields per input iPSC from the original protocol [31] and the modified version presented here. Differentiation protocols were tested in this study with iPSC lines SFC840-03-01 (STBCi026-B), SFC831-03-03 (STBCi024-B), SBNeo1, and SBAD3-01 and with Bioneer C10 (H266 C10 GC).